All In Biotech

Drug Trial Radar · NCT02292537

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy

Last checked: Nov 20, 2026Latest source record: Feb 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Nov 24, 2014

Primary completion

Feb 20, 2017

Study completion Feb 20, 2017

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Nov 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA). The secondary objective is to examine the safety and tolerability of nusinersen administered intrathecally to participants with later-onset SMA.

Conditions

  • Spinal Muscular Atrophy

Interventions

  • NusinersenDrug

    Administered by intrathecal (IT) lumbar puncture (LP) injection

  • Sham procedureProcedure

    Small needle prick on the lower back at the location where the IT injection is normally made

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15Time frame: Baseline and Month 15

Locations

24 sites in 10 countries. Site status is shown where the registry gives one.

  • UCLA Clinical and Translational Research Center

    Los Angeles, California

  • Lucile Packard Children's Hospital at Stanford

    Palo Alto, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia - Neurology

    Philadelphia, Pennsylvania

  • Children's Medical Center

    Dallas, Texas

  • Children's Hospital - London Health Sciences Centre

    London, Ontario, Canada

  • McGill University Health Centre-Glen Site-CIM

    Montreal, Quebec, Canada

  • Armand Trousseau Hospital, I-Motion, Clinical Trials Platform

    Paris, France

  • Universitatsklinikum Essen

    Essen, Germany

  • University Hospital Freiberg, Center for Paediatrics and Adolescent Medicine, Department of Neuropaediatrics and Muscular Disease

    Freiburg im Breisgau, Germany

  • The University of Hong Kong, Queen Mary Hospital, Department of Paediatrics and Adolescent Medicine

    Hong Kong, Hong Kong SAR, Hong Kong

  • AOU Policlinico G. Martino Dipartimento di Neuroscienze e Centro Clinico Nemo Sud

    Messina, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli-Universita Cattolica de Sacro Cuore-UOC Neuropsichiatre Infantile

    Rome, Italy

  • Hyogo College of Medicine

    Nishinomya-shi, Hyōgo, Japan

  • Tokyo Women's Medical University

    Shinjuku-ku, Tokyo, Japan

  • Seoul National University Children's Hospital

    Seoul, Korea, South Korea

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • University of Gothenburg, The Queen Silvia Children's Hospital

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.